Thr321
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr321  -  RPAP1 (human)

Site Information
PALALPVtPQkEWLH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3626629
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 )
Disease tissue studied:
luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 11 ) , cervical adenocarcinoma ( 11 ) , lung cancer ( 6 ) , non-small cell lung cancer ( 6 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
nocodazole ( 11 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

4

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

5

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

6

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

7

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

8

Guo A (2011) CST Curation Set: 12436; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

9

Possemato A (2010) CST Curation Set: 8990; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

10

Moritz A (2010) CST Curation Set: 9057; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

11

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

12

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

13

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

14

Moritz A (2006) CST Curation Set: 1785; Year: 2006; Biosample/Treatment: cell line, HEL/Flt3 inhibitor; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

15

Moritz A (2006) CST Curation Set: 1787; Year: 2006; Biosample/Treatment: cell line, HEL/-; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info